Combined HCC-MFCCC

Hepatocellular Carcinoma Clinical Trial

Official title:

Survival After Hepatectomy for Combined Hepatocellular Cholagiocarcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03178409
• Other study ID #: cHCC-MFCCC
• Status: Completed
• Phase: N/A
• First received: June 4, 2017
• Last updated: June 5, 2017
• Start date: January 1, 2004
• Est. completion date: May 15, 2017

Study information

• Verified date: June 2017
• Source: University of Milan
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Combined hepatocellular and mass-forming cholangiocarcinoma (cHCC-MFCCC) is a rare tumor. The aim of this study was the analysis of the outcome comparing such tumor with classic hepatocellular carcinoma (HCC) and mass-forming cholangiocarcinoma (MFCCC).

Description:

The institutional prospectively maintained database was queried, and 20 patients with cHCC-MFCCC were identified. A 2:1 match was performed with 40 patients operated in the same period for HCC, and with 40 operated for MFCCC. Only T1 or T2 patients N0 M0 were considered. Primary endpoint was the overall survival (OS) and disease-free survival (DFS).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: May 15, 2017
• Est. primary completion date: December 31, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• positive histology for cHCC-MFCCC, HCC, and MFCCC

• complete clinical, surgical, pathological and follow-up data.

Exclusion Criteria:

• patients preoperatively treated with chemotherapy, radiofrequency ablation or trans-arterial therapies were excluded.

• patients operated for recurrent disease and/or with non-radical surgery

• patients with missing data were also excluded

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Cholangiocarcinoma
• Hepatocellular Carcinoma
• Liver Carcinoma
• Surgery

Intervention

Procedure:
• Hepatectomy
Removal of a part of the liver

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Milan

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival analysis	Analysis of overall and disease-free survival of patients resected for cHCC-MFCCC versus those resected for HCC versus those resected for MFCCC	From 3 months after surgery up to 60 months after surgery